Neumora Therapeutics (NASDAQ:NMRA) Issues Quarterly Earnings Results

Neumora Therapeutics (NASDAQ:NMRA) released its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07), Briefing.com reports. During the same period in the prior year, the firm posted ($1.14) earnings per share.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA opened at $11.31 on Wednesday. The company’s fifty day moving average is $13.08 and its two-hundred day moving average is $11.41. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -4.42 and a beta of 3.92.

Insider Activity

In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares in the company, valued at $342,303. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Joshua Pinto sold 28,496 shares of Neumora Therapeutics stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total value of $331,408.48. Following the sale, the chief financial officer now directly owns 210,469 shares in the company, valued at $2,447,754.47. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the transaction, the director now owns 20,100 shares of the company’s stock, valued at approximately $342,303. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 110,538 shares of company stock valued at $1,390,513. Company insiders own 26.40% of the company’s stock.

Wall Street Analyst Weigh In

NMRA has been the subject of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Finally, HC Wainwright began coverage on shares of Neumora Therapeutics in a research report on Tuesday, October 1st. They set a “buy” rating and a $30.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.